GlassScriptPhysician profile
Kenneth W House
NPI 1043216393
$5,670.99
in general payments reported to CMS, 2019-2025
25 companies · $776 in 2025
The $776 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,398 · 2020: $141 · 2021: $284 · 2022: $1,311 · 2023: $1,233 · 2024: $528 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,536.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,719.12 | 2021-2025 | Resolute Onyx, Symplicity G3, Euphora |
| Boston Scientific Corporation | $1,526.31 | 2019-2025 | Watchman Flx, Farapulse |
| Heartflow, INC. | $512.65 | 2022-2025 | Ffrct |
| Abbott Laboratories | $409.06 | 2019-2025 | Aveir |
| E.R. Squibb & Sons, L.L.C. | $281.90 | 2019-2025 | Eliquis |
| Kestra Medical Technology Services, INC. | $168.26 | 2022-2024 | Assure Wcd |
| Amgen INC. | $129.15 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $124.61 | 2019-2025 | |
| Shockwave Medical, INC | $124.29 | 2021-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Edwards Lifesciences Corporation | $91.69 | 2020-2023 | Sapien 3 Ultra Resilia |
| Impulse Dynamics (USA) INC. | $90.06 | 2023 | Optimizer |
| Merck Sharp & Dohme LLC | $87.57 | 2023-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $74.70 | 2019-2023 | Farxiga |
| Abiomed | $48.83 | 2024 | Impella |
| Cvrx, INC. | $46.26 | 2023 | Barostim Neo System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $43.15 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $41.25 | 2019-2022 | |
| W. L. Gore & Associates, INC. | $28.19 | 2020-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $24.23 | 2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.61 | 2025 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $17.27 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $17.16 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.93 | 2020 | |
| Lantheus Medical Imaging, INC. | $15.54 | 2020 | |
| Philips North America LLC | $15.20 | 2025 | Coronary Other |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth House listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.